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Abstract
Epigenetic changes provide a frequent mechanism for transcriptional silencing of genes in cancer cells. We pre-
viously established that epigenetic mechanisms are important for control of group IIA phospholipase A2 (PLA2G2A)
gene transcription in human DU-145 prostate cells. In this study, we analyzed the involvement of such mech-
anisms in the regulation of five sPLA2 isozymes and the M-type receptor of sPLA2 (sPLA2-R) in human leukemic
Jurkat cells. These cells constitutively expressed sPLA2-IB, sPLA2-III, sPLA2-X, and sPLA2-R but not sPLA2-IIA and
sPLA2-V. Transcription of sPLA2-IIA and sPLA2-V was, however, detected after exposure of cells to the DNA de-
methylating agent, 5-aza-2′-deoxycytidine (5-aza-dC). Expression of sPLA2-IIA was further enhanced by additional
exposure to interferon-γ and blocked by inhibitors of specificity protein 1, nuclear factor κB, and Janus kinase/
signal transducer and activator of transcription–dependent pathways. Sequence analysis and methylation-specific
polymerase chain reaction of bisulfite-modified genomic DNA revealed two 5′-CpG sites (−111 and −82) in the
sPLA2-IIA proximal promoter that were demethylated after 5-aza-dC treatment. These sites may be involved in
the DNA binding of specificity protein 1 and other transcription factors. Similar findings after treatment of human
U937 leukemia cells with 5-aza-dC indicate that this mechanism of PLA2G2A gene silencing is not restricted to
Jurkat and DU-145 cells. These data establish that regulation of sPLA2-IIA and sPLA2-V in Jurkat and other cells
involves epigenetic silencing by DNA hypermethylation.
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Introduction
Secreted phospholipases A2 (sPLA2, phosphatide sn-2-acylhydrolases,
EC 3.1.1.4) belong to the superfamily of phospholipases that not
only catalyze production of bioactive lipid mediators of cell signal-
ing pathways but also function as receptor ligands, independently
of any enzymatic activity [1–5]. By way of these functions, the var-
ious sPLA2 isozymes play crucial roles in several physiological and
pathophysiological processes involving alterations in cellular prolifer-
ation, growth, differentiation, and apoptosis. The most thoroughly
characterized isozyme, sPLA2-IIA, is constitutively expressed in a va-
riety of cell types including chondrocytes, synoviocytes, mesangial
cells, astrocytes, and smooth muscle cells (for review [4]).
Recognition that expression of sPLA2-IIA is increased in numer-
ous cancer cells has formed the basis of the sPLA2-IIA pro-oncogenic
activity concept [6–12]. The precise role of the enzyme in tumori-
genesis, nevertheless, remains unclear. In human pancreatic cancer
cells and gastric adenocarcinoma, expression of sPLA2-IIA is associ-
ated with prolonged survival and reduced tendency to metastasis,
suggesting antioncogenic properties [13,14]. Moreover, sPLA2-IIA
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is not appreciably expressed in a number of cancer cell lines including
human leukemia Jurkat T cells, monocytic U937 cells [15–17], fibro-
sarcoma HeLa cells [18], and prostate cancer DU-145 cells [9,19].
Recently, we established that lack of sPLA2-IIA expression and
failure of cytokines to induce sPLA2-IIA expression in malignant
DU-145 prostate cells can be explained by an epigenetic silencing
regulatory mechanism and not by PLA2G2A gene mutations con-
nected with a failed expression of intact sPLA2-IIA protein [19].
Such mechanisms involve aberrant methylation of cytosines belong-
ing to 5′-CpG islands, short stretches of DNA rich in 5′-CpG di-
nucleotides, and often associated with gene promoters (for review
[20,21]). In cancer cells, the methylation may retard expression of
genes critical to cell proliferation and apoptosis [21].
With the above considerations inmind, we proposed that epigenetic
mechanisms are involved in the silencing of sPLA2-IIA in a number
of so-called “sPLA2-IIA–negative” cells. To address this hypothesis,
we analyzed the expression of sPLA2-IIA and four other sPLA2 iso-
zymes (IB, III, V, and X) in connection with the M-type receptor
of sPLA2 (sPLA2-R) in cytokine-primed Jurkat cell lines before and
after treatment with demethylating agent, 5-aza-2′-deoxycytidine (5-
aza-dC). We also determined the methylation status of several distinct
5′-CpG sites in the proximal sPLA2-IIA promoter region.
Materials and Methods
Materials
Recombinant human interleukin 1β (IL-1β), interleukin 6 (IL-6),
tumor necrosis factor α (TNF-α), and interferon γ (IFN-γ) were
purchased from Roche Diagnostics Applied Science (Mannheim,
Germany). PD98059, Janus kinase (Jak) inhibitor I, phorbol-12-
myristate 13-acetate (PMA), SP-600125, and H-1152 were obtained
from Calbiochem (San Diego, CA). Forskolin, 5-aza-dC, mithramy-
cin A, and caffeic acid phenethyl ester (CAPE) were purchased from
Sigma-Aldrich (Deisenhofen, Germany). Phorbol-12-myristate 13-
acetate, PD98059, forskolin, SP-600125, mithramycin A, Jak inhib-
itor I, and CAPE were dissolved in dimethyl sulfoxide (DMSO). The
final concentrations of solvents were 0.3% or less. Controls using
DMSO alone were run in all cases.
Cell Culture and Incubation
Jurkat (human T lymphocyte acute leukemia) and U937 (human
hystiocytic lymphoma) cell lines were purchased from German Col-
lection of Microorganisms and Cell Cultures (Berlin, Germany). They
were cultured in a standard cell medium RPMI-1640 supplemented
with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in a humid-
ified atmosphere of 5% CO2. For all experiments, exponentially grow-
ing subconfluent cells were used at passages 5 to 8.
For 5-aza-dC treatment, cells were cultured in RPMI 1640 cell
medium with 10% fetal calf serum and 5-aza-dC added to the final
concentration of 1 to 10 μM from a freshly prepared 10-mM stock
solution. After 3 days, during which the culture medium containing
5-aza-dC was renewed once each day, the cells were harvested and
analyzed for sPLA2-IIA protein and mRNA levels.
RNA Extraction and Reverse Transcription–Polymerase Chain
Reaction Analysis of sPLA2 Enzyme Expressions
RNA was isolated after lysis of Jurkat T cells in TRI Reagent
(Sigma-Aldrich) according to the manufacturer’s instructions. Iso-
lated RNA was converted to cDNA using the GeneAmp RNA-
PCR Kit (PerkinElmer LAS GmbH, Jügesheim, Germany). Portions
of the reverse-transcribed reaction products were then amplified by
polymerase chain reaction (PCR) for the identification of sPLA2-IB,
-IIA, -III, -V, -X, the M-type of the sPLA2 receptor (sPLA2-R), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH ) as a house-
keeping gene. The applied primer pairs are summarized in the Table 1.
The oligonucleotides used for analysis of mRNA were synthesized
according to published nucleotide sequences of human sPLA2-IB,
sPLA2-IIA, sPLA2-III, sPLA2-V, sPLA2-X, sPLA2-R, and GAPDH
genes (http://www.ensembl.org/index.html). Primer pairs for PCR
were applied in a final concentration of 0.8 μM. The conditions
for amplification were as follows: 40 cycles at 94°C for 30 seconds,
68°C for 30 seconds, and 72°C for 1 minute. Buffers and reagents
were fromGeneAmp Kit (PerkinElmer LAS GmbH). Amplified prod-
ucts were analyzed by electrophoresis on agarose gels.
Quantitative Determination of sPLA2-IIA by Enzyme-Linked
Immunosorbent Assay
Release of sPLA2-IIA protein into the culture medium was deter-
mined using an enzyme-linked immunosorbent assay (ELISA) kit ac-
cording to the manufacturer’s instructions (Cayman Chemical, MI).
Culture medium was removed, centrifuged for 10 minutes at 400g to
remove cell debris, and used for sPLA2-IIA protein determinations.
Total cell protein was determined using a bicinchoninic acid assay kit
(Sigma-Aldrich).
Searching for 5′-CpG Islands and Potential Binding Sites for
Transcription Factors in Proximal Promoter Regions of sPLA2
Isozymes and M-type Receptor of sPLA2
To address the question of whether 5′-CpG islands are present
in the promoters of the sPLA2 isozymes and sPLA2-R, we used
MethPrimer software (http://www.urogene.org/methprimer) to ana-
lyze the promoter regions −1000 to +200 relative to the transcription
starting sites of each gene [22]. We also used TFSEARCH software
[23,24] and an object-oriented transcription factors search (ooTFD)
software [25] to assess whether the proximal promoter of PLA2G2A
contains binding sites for transcription factors known to be crucial
for the sPLA2-IIA expression.
DNA Methylation Analysis of Selected 5′-CpG Sites in the
Proximal sPLA2-IIA Promoter Region
Genomic DNA was extracted from control and 5-aza-dC–treated
Jurkat cells using DNazol (Invitrogen Life Technologies, Karlsruhe,
Table 1. Sequences of the Applied Forward (f ) and Reverse (r) Primers.
Genes Sequences Size (bp)
PLA2G1B 5′-AAA TGA TCA AGT GCG TGA TCC-3′ (f ) 243
5′-TTG CTG CTA CAG GTG ATT GC-3′ (r)
PLA2G2A 5′-GTG ATC ATG ATC TTT GGC CTA CTG CA-3′ (f ) 411
5′-TCT CCC TCG TGG GGA GCA ACG ACT-3′ (r)
PLA2G3 5′-ACAACTCTTCTATGCCTGG-3′ (f )′ 256
5′-TGTGACATCCCTAACTTCC-3′ (r)
PLA2G5 5′-GGG CTG CAA CAT TCG CAC AC-3′ (f ) 278
5′-CCT CTC TCA GGA ACC AGG CAG-3′ (r)
PLA2G10 5′-CCA TCG CCT ATA TGA AAT ATG G-3′ (f ) 295
5′-TAG GAA CTG GGG GTA GAA GAG-3′ (r)
PLA2G1R 5′-CAG AAG AAA GGC AGT TCT GGA TTG-3′ (f ) 496
5′-AAA GCC ACA TCT CTG GCT CTG ATT-3′ (r)
GAPDH 5′-CGG AGT CAA CGG ATT TGG TCG TAT TG-3′ (f ) 439
5′-GCA GGA GGC ATT GCT GAT GAT CTT G-3′ (r)
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Germany) following the manufacturer’s instructions. Sodium bisul-
fite treatment of the genomic DNA was performed using the Methyl-
Detector kit from Active Motif (Carlsbad, CA) [26–28].
To amplify the bisulfite-modified DNA, a seminested PCR was
performed with primers covering regions within the proximal pro-
moter region of the sPLA2-IIA gene from −351 to +152 relative to
the transcription start site [29]. As extrinsic primers, 5′-CTC ATA
CAT ATC AAA TCA T-3′ and 5′-GTA ATT GGT AGT TTT
TTT G-3′, and as intrinsic primers, 5′-CTC ATA CAT ATC AAA
TCA T-3′ and 5′-GTA AAT GAG TTT ATA GTT TG-3′, were ap-
plied in a final concentration of 0.8 μM. The conditions of PCR
were as follows: 20 cycles at 95°C for 45 seconds, 44°C for 60 sec-
onds and 72°C for 45 seconds using the extrinsic primers, and 35 cy-
cles at 95°C for 30 seconds, 45°C for 45 seconds, and 72°C for
30 seconds using the intrinsic primers. The buffers and reagents
were from GeneAmp Kit (PerkinElmer LAS GmbH). The PCR
products were purified using a QIAquick PCR purification kit
(Qiagen GmbH, Hilden, Germany). DNA sequences of both strands
were analyzed with the ABI PRISM 310 Genetic Analyzer (Perkin-
Elmer Applied Biosystems, Foster City, CA). To verify the efficiency
of bisulfite treatment, the sequence of bisulfite-treated genomic
DNA was compared with that of untreated genomic DNA. As a
further control, Jurkat DNA treated in vitro with Sss I methyltrans-
ferase and purchased from New England BioLabs Inc. (Ipswich, MA)
was used.
In addition to sequence analysis of bisulfite-modified genomic
DNA, methylation-specific PCR was performed. For this purpose,
the following forward (f ) and reverse (r) primers were designed
and applied:
5′-TGG TAT TAG TTA TTG ATA CGT-3′, f for methylated
5′-CpG (−186);
5′-CGG TAT TAG TTA TTG ATA TGT-3′, f for unmethyl-
ated 5′-CpG (−186);
5′-ATT ATT TAG GGG TAT GGG CGA-3′, f for methylated
5′-CpG (−111);
5′-ATT ATT TAG GGG TAT GGG TGA-3′, f for unmethyl-
ated 5′-CpG (−111);
5′-TTT TGA GTT TAT TAA TTG ATT ACG T-3′, f for
methylated 5′-CpG (−82);
5′-TTT TGA GTT TAT TAA TTG ATT ATG T-3′, f for un-
methylated 5′-CpG (−82);
5′-CTC CAA AAT TAT ATC CCC AAA-3′, r primer.
The conditions of amplification for methylation analysis were as
follows: 40 cycles at 95°C for 30 seconds, 50°C for 30 seconds,
and 72°C for 30 seconds in the case of the primer pairs to analyze
the 5′-CpG sites at positions −186 and −82. In case of the 5′-CpG
site at position −111, a touchdown PCR with an annealing temper-
ature between 45 and 50°C was performed. Finally, PCR products
were analyzed by electrophoresis on agarose gels.
Data Analysis
Data were analyzed by one-way analysis of variance coupled with
Dunnett’s post hoc test to compare each experimental group with a
nominated control group using SPSS 14.0 software. Differences were
considered significant at P < .05.
Results
Basal and Cytokine-Induced Expression of Secreted
Phospholipases A2 and Phospholipase A2 Receptor in
Human Jurkat Cells
According to our reverse transcription–PCR (RT-PCR) data, Jurkat
cells constitutively expressed sPLA2-IB, sPLA2-III, and sPLA2-X iso-
zymes, whereas no transcripts of sPLA2-IIA and sPLA2-V were detect-
able (Figure 1). A moderate stimulation of sPLA2-IIA and sPLA2-V
transcription occurred after exposure of cells to IFN-γ. The sPLA2-
R was constitutively expressed and stimulated by all cytokines that
were examined (Figure 1). Of note, the level of sPLA2-X mRNA de-
creased considerably after treatment of Jurkat cells with TNF-α.
Preincubation of Jurkat cells with the methyltransferase inhibitor, 5-
aza-dC, induced the transcription of sPLA2-IIA, increased exist-
ing expression of sPLA2-R, but did not significantly affect expression of
sPLA2-IB, sPLA2-III, sPLA2-V, or sPLA2-X (Figure 1). The failed strong
effect of 5-aza-dC treatment on sPLA2-IB, sPLA2-III, and sPLA2-X ex-
pression was reproducible using RT-PCR with lower amounts of ampli-
fication cycles (30 instead of 40 cycles to exclude a possible end point
amplification; data not shown). The additional presence of proinflam-
matory cytokines, IFN-γ, TNF-α, IL-1β, or IL-6, was required to in-
duce sPLA2-V by 5-aza-dC treatment (Figure 1).
Similar results to the above at the protein level for sPLA2-IIA were
obtained as determined using a commercially available ELISA kit.
After exposure of Jurkat cells to IFN-γ for 72 hours, the level of
sPLA2-IIA secreted into the culture medium increased significantly
from 8.1 ± 2.9 to 75.1 ± 45.6 pg/mg cell protein (Figure 2). A strong
up-regulation of sPLA2-IIA resulted after simultaneous treatment
of cells with cytokines and 5-aza-dC (Figure 2). The sPLA2-IIA pro-
tein level released into culture medium increased from 708.4 ±
Figure 1. Agarose gel electrophoresis of RT-PCR amplificates of
different secreted phospholipase A2 isozymes (sPLA2-IB, sPLA2-
IIA, sPLA2-III, sPLA2-V, and sPLA2-X) and the M-type receptor of
sPLA2 (sPLA2-R) in comparison to GAPDH mRNA in control and
cytokine-primed Jurkat cells, with and without exposure to the
DNA demethylating agent, 5-aza-dC. Cells were incubated for
72 hours with vehicle, 10 μM 5-aza-dC, or 5-aza-dC in combination
with different proinflammatory cytokines at final concentrations of
25 ng/ml. Lane 1 in both 5-aza-dC–treated and untreated cells repre-
sents controls (without addition of cytokines) for cytokine-treated
cells. Lanes 2 to 6 represent cells treated with IFN-γ, IL-1β, IL-1β +
TNF-α (both at 12.5 ng/ml), TNF-α, and IL-6, respectively. Data are
representative of at least three independent experiments giving
similar results.
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112.0 pg/mg cell protein in cells treated with 5-aza-dC for 72 hours
to 5084.4 ± 1149.0 pg/mg cell protein when cells were exposed to
IFN-γ and 5-aza-dC during the same period.
A comparison of sPLA2-IIA mRNA expression and protein release
in cells treated with 5-aza-dC combined with IFN-γ indicates stron-
ger effects on sPLA2-IIA protein release (Figure 2) than on mRNA
level (Figure 1). A possible reason for this difference is that after
72 hours of incubation when the protein release and sPLA2-IIA
mRNA levels were determined, the peak level of mRNA was earlier
and transient, whereas the amount of sPLA2-IIA protein in the cul-
ture medium reflects the accumulation of the released enzyme during
the incubation period of 72 hours. This conclusion is consistent with
findings of Vial et al. [30], who observed a peak level of sPLA2-IIA
mRNA at 16 hours and its decline at 32 hours, whereas the sPLA2-
IIA protein level remained high until the end of incubation. Analysis
of the active concentration range for IFN-γ indicated that IFN-γ–
mediated up-regulation of sPLA2-IIA expression in Jurkat cells was
dose-dependent, with a half-maximal effect at ∼6 ng/ml of IFN-γ
(Figure 3A).
Regulation of sPLA2-IIA Expression by the Activity of
Signaling Pathways
A marked increase of sPLA2-IIA protein release occurred when 5-
aza-dC– and IFN-γ–treated cells were incubated with the mitogen-
Figure 2. Bar graphs showing effects of the demethylating agent, 5-aza-dC, alone and in combination with proinflammatory cytokines on
sPLA2-IIA protein levels in conditioned culture medium of Jurkat cells. Cytokines were added at a final concentration of 25 ng/ml. Cells
were exposed to 10 μM 5-aza-dC or vehicle (DMSO) for 6 and 72 hours. The insert shows at higher resolution the results for sPLA2-IIA
protein release in cells that were not exposed to 5-aza-dC. Results are means ± SDs of three separate analysis in quadruplicates (n =
12). *P < .05 versus cells not exposed to 5-aza-dC; #P < .05 versus cells exposed to 5-aza-dC but not to cytokines.
Figure 3. Dose-dependent effects of IFN-γ (A) and effects of pharmacological manipulations of cell signaling pathways (B) on sPLA2-IIA
protein release from Jurkat cells treated with 5-aza-dC. Concentrations of sPLA2-IIA protein in cell incubates determined after a 72-hour
exposure of cells to 10 μM 5-aza-dC and increasing concentrations of IFN-γ are shown in panel A. Effects of cell signaling activators and
inhibitors on the levels of sPLA2-IIA after a 72-hour incubation with 25 ng/ml IFN-γ and 10 μM 5-aza-dC are shown in panel B. Forskolin
(10 μM), PMA (30 ng/ml), H-1152 (10 μM), PD98059 (PD98; 50 μM), indirubin (100 nM), SP-600125 (SP600; 5 μM), mithramycin A
(Mithram; 250 nM), CAPE (25 μM), or Jak inhibitor I (Jak Inhib; 1 μM) were added simultaneously with IFN-γ and 5-aza-dC. The data shown
are the means ± SDs of analysis in triplicate and are representative of three independent experiments.
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activated/extracellular response protein kinase/extracellular signal–
regulated kinase 1/2 inhibitor, PD-98059 (Figure 3B). Expression
was also increased, albeit to a lesser extent, after incubation of 5-
aza-dC– and IFN-γ–treated cells with H-1152, a Rho-kinase inhib-
itor, and SP-600125, a Jun N-terminal kinase inhibitor.
An inhibition of sPLA2-IIA protein release was found when Jurkat
cells treated with 5-aza-dC and IFN-γ were exposed simultaneously
to forskolin (Figure 3B). A similar inhibitory effect was seen by PMA
as an activator of protein kinase C. Finally, mithramycin A, an inhib-
itor of specificity protein 1 (Sp1) binding to DNA, CAPE, an inhib-
itor of NF-κB, and Janus kinase inhibitor I completely abolished the
reexpression of sPLA2-IIA induced by 5-aza-dC and IFN-γ in Jurkat
cells (Figure 3B).
Effects of 5-aza-dC Treatment on the Methylation Status of
Selected 5′-CpG Sites in the Proximal sPLA2-IIA Promoter
The analyses using MethPrimer demonstrated that distinct 5′-
CpG islands are present only in PLA2G10 and PLA2-R genes. No
5′-CpG islands were detected in the promoter regions of PLA2G2A
(Figure 4A), PLA2G1B, PLA2G3, and PLA2G5 genes (data not
shown). Furthermore, using TFSEARCH and ooTFD software, we
found that the sPLA2-IIA promoter region from −260 to +20
contained a number of potential binding sites, including those for
signal transducer and activator of transcription (STAT) [−255,
−246], NF-κB [−251, −241], CAAT-enhancer–binding protein β
(C/EBP-β) [−177, −169], NF-Y [−114, −97], Sp1 [−86, −76], and
γ-IRE [−197, −189] (Figure 4A).
In Figure 4B, data of sequence analyses of 5′-CpG sites −186,
−111, −82, and +8 in the reverse strand are shown. A complete con-
version of guanine into adenine demonstrated that the bisulfite mod-
ification was effective. Similar results were obtained by analysis of the
forward strand (data not shown). As a positive control, enzymatically
hypermethylated genomic DNA from Jurkat cells was used. Here,
the residual unmethylated portions of 5′-CpG sites −111, −82,
and +8 disappeared completely as a sign of total methylation of these
sites (Figure 4B).
Finally, sequence analyses of genomic DNA from Jurkat cells dem-
onstrated that the 5′-CpG sites −186, −111, −82, and +8 were meth-
ylated to ∼100%, ∼83%, ∼79%, and nearly 100%, respectively. After
5-aza-dC treatment for 72 hours, the methylated portions of 5′-CpG
sites −111, −82, and +8 decreased to ∼20%, 0%, and ∼83%, respec-
tively. The methylation status of the 5′-CpG site −186 did not
changed significantly after exposure of cells to 5-aza-dC (Figure 4B).
The data obtained by sequence analyses were supported by
methylation-specific PCR, showing that the 5′-CpG −82 site was
strongly demethylated and the −111 site partially demethylated by
5-aza-dC; in contrast, no demethylation of the 5′-CpG −186 site
was evident (Figure 4C ).
Reexpression of sPLA2-IIA in Human U937 Leukemia Cells
As shown in Figure 5, treatment of U937 leukemia cells with 5-
aza-dC restored sPLA2-IIA expression, and this was further markedly
facilitated by simultaneous addition of IFN-γ. The levels of sPLA2-
IIA released into the medium of these cells were distinctly lower
compared with those released into the medium by Jurkat cells.
The pattern of reexpression was, however, overall qualitatively similar
in both leukemic cell lines, except that IL-6 increased sPLA2-IIA re-
lease in Jurkat cells, but not in U937 cells, and TNF-α increased
sPLA2-IIA release in U937 cells, but not in Jurkat cells (Figures 2
and 5).
Discussion
In this study of five secreted phospholipases A2 (groups IB, IIA,
III, V, and X) in T-lymphoblastic Jurkat cells, we show that epigenetic
mechanisms regulate the expression of two isozymes, sPLA2-IIA and
sPLA2-V. Scanning of 5′-flanking promoter regions (−1000; +200) of
corresponding PLA2G2A and PLA2G5 genes indicated a relatively
low number of 5′-CpG sites and no 5′-CpG islands. In contrast,
PLA2G10 and PLA2-R genes are rich in 5′-CpG islands (data not
shown). However, the constitutive expression of PLA2G10 and
PLA2-R and failed strong effects of 5-aza-dC on the expression of
both genes argue against a significant involvement of epigenetic
mechanism such as hypermethylation in the regulation of these genes
in Jurkat cells.
Nevertheless, that the PLA2G2A and PLA2G5 genes have no 5′-
CpG islands and the presence of clusters of methylated 5′-CpG sites
or even a single site—instead of 5′-CpG islands within the binding
regions of crucial transcription factors—can be sufficient for gene si-
lencing as shown for other genes [31–33]. Such sites may also be
responsible for silencing of PLA2G2A and PLA2G5.
By using TFSEARCH [23,24] and ooTFD [25] software, we con-
firmed a number of specific cognate binding sites in the proximal
promoter region from −260 to +20 of the PLA2G2A gene for tran-
scription factors known to be important for the PLA2G2A promoter
activity, including Sp1, NF-κB, STAT, and C/EBP-β [4,18,19,29].
Two additional binding sites were found for NF-Y, also called
CCAAT box-binding factor [34], and γ-interferon response element
(γ-IRE) in the same region (Figure 4A). The former transcription
factor, NF-Y, is considered to be important for the PLA2G2A pro-
moter activity [18]. How far the latter transcription factor, γ-IRE, in
addition to previously examined transcription factors, is actually es-
sential for promoter activity, however, requires further investigation.
The data from sequence analyses and methylation-specific PCR
demonstrated that four 5′-CpG sites (−186, −111, −82, and +8) at
this sPLA2-IIA promoter region were almost completely methylated.
After 5-aza-dC treatment, two of the sites (−82 and −111) became
quantitatively demethylated, whereas some demethylation occurred
at the +8 site and negligible demethylation at the −186 site.
The demethylation of 5′-CpG sites at −82 and −111 of the sPLA2-
IIA proximal promoter regions by 5-aza-dC may be of special impor-
tance. As shown in Figure 4A, site −82 is within the potential Sp1
binding domain, 5′-GACCACGCC-3′, near the TATA box of the
sPLA2-IIA promoter [18,35], whereas site −111 is part of the DNA
binding region for NF-Y/CCAAT box-binding factor. Recently, it
was demonstrated that binding of both transcription factors is cru-
cial for full induction of the promoter activity of the human PHGDH
gene in HeLa cells [36]. Possibly, therefore, hypermethylation of
5′-CpG sites at −82 and −111 of the proximal PLA2G2A promoter
may result in failure of both transcription factors to bind at putative
Sp1 and NF-Y binding sites, with subsequent absence of sPLA2-IIA
expression. The importance of Sp1 binding in the regulation of
sPLA2-IIA expression is supported by our findings that blockade of
Sp1 binding sites by mithramycin A completely abolished the induc-
tion of sPLA2-IIA by 5-aza-dC and IFN-γ. Mithramycin A acts as an
inhibitor of Sp1. It binds to 5′-CpG sites and 5′-CpG–rich tracts as a
dimer that forms in the presence of magnesium [37]. The importance
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Figure 4. Methylation of the proximal promoter of the PLA2G2A gene. (A) Location of 5′-CpG sites and potential binding regions for
transcription factors in the proximal promoter of PLA2G2A gene was assessed using MethPrimer and TFSEARCH software as described
in the Materials and Methods section. The gene sequence is numbered [−900, +200 bp] relative to the transcription start site [29] and
the proximal promoter region [−260, +20] of PLA2G2A. Positions of potential binding sites for transcription factors, STAT, NF-κB, C/
EBP-β, NF-Y, Sp1, and γ-IRE, are illustrated. (B) Methylation status of selected 5′-CpG sites in the proximal PLA2G2A promoter of Jurkat
genomic DNA before and after exposure to 10 μM 5-aza-dC as described in the Materials and Methods section. Representative results
of sequence analyses of the bisulfite-treated genomic reverse DNA strands are shown. Arrows indicate the conversion of reverse 5′-CpG
sites, −186, −111, −82, and +8, in dependence on the methylated status. (C) Methylation-specific PCR analyses of genomic DNA
before and after exposure of Jurkat cells to 5-aza-dC. M or U indicate the presence of methylated or unmethylated 5′-CpG sites.
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of NF-Y for sPLA2-IIA promoter activity, however, still has to be an-
alyzed more thoroughly.
Our findings that the Jak inhibitor I and CAPE, an inhibitor of
NF-κB, completely blocked the 5-aza-dC– and IFN-γ–mediated in-
duction of sPLA2-IIA (Figure 3) suggest that for an optimal sPLA2-
IIA expression, in addition to Sp1, the activities of NF-κB and STAT
are necessary. The activities of these transcription factors are modu-
lated by upstream cell signaling pathways. As demonstrated in a va-
riety of cell types—from human aortic smooth muscle cells, HepG2
hepatoma cells, and prostate epithelial cells to human malignant
prostate cell lines (PC-3 and LNCaP)—all of these pathways have
negative regulatory influences on sPLA2-IIA expression [4,19]. Our
data indicate the presence of similar negative regulatory influences on
the expression of sPLA2-IIA in Jurkat cells.
Our data, however, also indicated different effects of cAMP/protein
kinase A (PKA) signaling pathway on the sPLA2-IIA expression in
Jurkat cells compared with other cell types [38,39]. In normal pros-
tate epithelial cells and tumor prostate PC-3 cells, for example,
activation of cAMP/PKA by forskolin in the presence of IFN-γ re-
sults in a synergistic up-regulation of sPLA2-IIA [19]. In contrast,
an inhibitory effect of forskolin has been observed in malignant
prostate LNCaP cells [19] and lipopolysaccharide (LPS)–stimulated
alveolar macrophages [40], a response similar to the effect observed
in the present study in Jurkat cells. The reason for the divergent
effects of the cAMP/PKA signaling pathway among different cell
types presently remains unclear. Interestingly, trichostatin A, an in-
hibitor of histone deacetylase activity, decreased the LPS-stimulated
sPLA2-IIA expression in alveolar macrophages [40]. It is known
that histone deacetylase activity is inhibited by PKA-dependent
phosphorylation [41]. This suggests that histone deacetylation as
a further epigenetic mechanism may be involved in the forskolin-
mediated effect on the LPS-stimulated sPLA2-IIA expression in al-
veolar macrophages. Whether a similar mechanism is also acting in
Jurkat cells remains unknown.
The importance of diverse cell signaling cascades in the regulation
of sPLA2-IIA expression underscores the opportunity that, in addi-
tion to the direct demethylation of 5′-CpG sites in the PLA2G2A
promoter itself, indirect mechanisms may also be responsible for
the reexpression of sPLA2-IIA mediated by 5-aza-dC. It is con-
ceivable that this may involve demethylation of 5′-CpG sites in
the promoters of corresponding upstream signaling components or
transcription factors. Indeed, our search of 5′-CpG islands confirmed
the presence of distinct islands in gene promoters of relevant regula-
tors of sPLA2-IIA expression, including Sp1, NF-κB p65, Jak/STAT,
Rho-kinase, and C/EBP-β (data not shown).
Interferon response elements have also been identified to exhibit
5′-CpG islands [42]. Of note, the sPLA2-IIA promoter at positions
[−197, −189] has a potential binding site for the γ-IRE (Figure 4A).
It is interesting that, in leukemic cells, such regulatory elements were
down-regulated due to hypermethylation of 5′-CpG motifs in their
promoter regions [42]. Therefore, it is possible that IREs are also in-
volved in the restoration of sPLA2-IIA expression by 5-aza-dC.
In general, the regulation of the PLA2G2A promoter is complex
and includes species- and cell type–specific mechanisms of induction
by proinflammatory mediators (for review [3,4,29]). TNF-α and IL-
1β effectively up-regulate the expression of sPLA2-IIA in numerous
cell types; moreover, a strong up-regulation of sPLA2-IIA was found
solely by IFN-γ [4] including cell lines with reexpressed PLA2G2A
after 5-aza-dC treatment such as malignant prostate DU-145 cells
[19] or Jurkat and U-937 cells as shown here.
The observation that the inhibition of DNA methylation can re-
store the cytokine-mediated effects on sPLA2-IIA and sPLA2-V ex-
pression may have important implications in the development of
novel strategies to treat leukemia. Cytokines are known to be crucial
in a variety of cellular and molecular events [43,44]. For example,
IFN-γ stimulates antiproliferative pathways in tumor cell lines [45].
Expression data in immortalized fibroblasts revealed that among
genes with methylation-dependent silencing, approximately 50%
were regulated through interferon-dependent growth-suppressive
signaling pathways [46]. Furthermore, the efficiency of cytokine-
mediated effects can be amplified in cells treated with 5-aza-dC. For
example, 5-aza-dC and IFN-γ at relatively low individual concen-
trations acted in a proapoptotic and synergistic manner in resistant
neuroblastoma, medulloblastoma [47], and metastatic uveal mela-
noma cells [48].
Finally, our current data demonstrate that epigenetic silencing of
PLA2G2A and PLA2G5 is not restricted to Jurkat cells but also
occurs in leukemic U937 cells. The pathophysiological relevance of
PLA2G2A and PLA2G5 silencing in malignant cells remains unclear.
Nevertheless, the finding of the present study support the growing
body of evidence that the antioncogenic and proapoptotic prop-
erties of sPLA2 isozymes may have importance for novel strategies
targeting defective apoptosis pathways in tumors [49–53]. It should
be noted, however, that 5-aza-dC treatment induces not only some
well-established antioncogenic genes but also a set of prometastatic
genes [54]. Therefore, establishing in detail which genes are up-
regulated by 5-aza-dC treatment is important to understanding the
overall prooncogenic or antioncogenic effects of such a treatment.
In conclusion, the data of this study indicate that DNA methyla-
tion plays a crucial role in the regulation of sPLA2-IIA and sPLA2-V
in Jurkat and U937 cells. Whether a direct hypermethylation of sin-
gle 5′-CpG sites of the proximal promoter may explain sPLA2-IIA
silencing in Jurkat and other cells or whether the hypermethylation
of 5′-CpG sites in the promoter of corresponding upstream acting
transcription factors or signaling components are responsible requires
further investigation.
Figure 5. Effects of 5-aza-dC alone and in combination with proin-
flammatory cytokines on sPLA2-IIA protein levels released by U937
leukemia cells. Cytokines were added at a final concentration of
25 ng/ml, and cells were exposed to 10 μM 5-aza-dC or vehicle
(DMSO) for 72 hours, respectively. Results are the means ± SDs
of three separate analysis in quadruplicates (n = 12). #P < .05
versus cells exposed to 5-aza-dC but not to cytokines.
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